51 results about "Pulmonary artery" patented technology

The technology herein provides various embodiments that relate to a method of treating pulmonary hypertension in a subject in need thereof, comprising administering to the subject an effective amount of BX-912 (N-[3-[[5-bromo-4-[2-(1H-imidazol-5-yl)ethylamino]-2-pyrimidinyl]amino]phenyl]pyrrolidine-1-carboxamide).

The application provides a pulmonary artery tissue-derived cell, an organoid and a construction method and application thereof. The pulmonary artery intimal stripping tissue organoid structure obtained by the preparation method is clear, has consistent cell types as the source tissue, is close to the original tissue, is convenient for researchers to operate, and thus has good practical application value.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

A pyrrolopyrimidine or pyrrolopyridine derivative and its medical use. Specifically, the compound has the structure shown in formula I, has good inhibitory effect on focal adhesion kinase (FAK), and can inhibit its related signal pathways, and can be prepared for treating or preventing diseases related to cancer, pulmonary arterial hypertension, pathological angiogenesis, etc., and can be particularly used for treating diseases caused by excessive or abnormal cell proliferation, such as tumors or cancers.

There are provided a composition for preventing and treating heart disease due to pulmonary hypertension, and a functional preparation containing the same. The composition includes pimobendan, enalapril, torsemide, and spironolactone, and is thus effective in preventing and treating heart disease and pulmonary hypertension of animals.

The present invention discloses the use of a compound of formula I sertaconazole or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for preventing or treating oxidative stress-related cardiovascular diseases. Specifically, the present invention relates to the use of said compound in the preparation of a medicament for preventing or treating oxidative stress-related vascular diseases, including but not limited to acute coronary syndrome, alcoholic heart dysfunction, hypoxic pulmonary arterial hypertension, heart failure, drug-induced cardiotoxicity and stroke, especially acute heart failure.

A system for determining a global hypoperfusion index (GHI) includes an arterial blood pressure sensor, a ventricular blood pressure sensor, an oximetry module, and an integrated hardware unit including a system processor and a system memory. The system memory includes instructions that cause the system to receive arterial hemodynamic data, ventricular hemodynamic data, and blood oxygen saturation data. One or more right ventricular pressure features, one or more pulmonary artery pressure features, one or more cardiac output parameters, and one or more venous oxygen saturation parameters are derived from the arterial hemodynamic data, the ventricular hemodynamic data, and the blood oxygen saturation data. The GHI is derived by using a predictive decision model based upon the one or more right ventricular pressure features, the one or more pulmonary artery features, the one or more cardiac output parameters, and the one or more venous oxygen saturation parameters.

Systems and methods are provided for treating conditions such as heart failure and / or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The system may include sensors to determine the degree of occlusion of the superior vena cava. The occlusion system may be used to reduce volume in a heart and facilitate a cardiac procedure. The occlusion system may be used to relieve an overloaded chamber during and / or after deploying a VAD.

The present disclosure provides a transcatheter device including: an anchor (200) anchored to an inner wall of an inferior vena cava (IVC); and a main shaft (10) having a proximal shaft (110) that extends from the anchor (200) toward a tricuspid valve (TV) along a cavotricuspid isthmus (CTI) of a heart, a middle shaft (120) that extends from the proximal shaft (110), passes through the TV, and has a spacer (300) preventing a reverse flow in the TV mounted thereon, and a distal shaft (130) that extends from the middle shaft (120) into a pulmonary artery (PA), and the distal shaft (130) of the main shaft (100) includes a first distal part (131) that extends in a curved shape having a predetermined curvature from the middle shaft (120), a second distal part (132) that extends from the first distal part (131) and bends at point B1, which is one point that is over and surrounds an aorta, toward the proximal shaft (110), and a third distal part (133) that extends from the second distal part (132) toward the proximal shaft (110).

The application relates to a pulmonary artery virtual angiography generation method and system based on a generative adversarial network. The method comprises the following steps: acquiring processed unpaired plain CT images and real CTPA images as sample data and dividing the sample data into a training set and a verification set; sampling original plain CT images and original CTPA images from the training set and inputting the original plain CT images and the original CTPA images into a generative adversarial network; generating a virtual CTPA image through a generator, performing CTPA domain discrimination through a first discriminator, and reconstructing a plain CT image through an inverse generator; calculating a multi-objective loss function based on an output result, updating network parameters and loss weights, and iteratively training until convergence to obtain a pulmonary artery virtual angiography generation model; and inputting a target plain CT image into the model to output a target virtual CTPA image.

The embodiment of the application provides a right ventricular assist system and a control method of a right ventricular assist device. The right ventricular assist device comprises a blood-out cage, a blood-in cage, a pumping assembly and a driving assembly. The driving assembly, the pumping assembly and the blood-in cage are located in the inferior vena cava, and the blood-out cage is located in the pulmonary artery. The driving assembly drives the pumping assembly to rotate in the clockwise direction, pushes the blood from the blood-in cage into the blood-out cage, and then into the pulmonary artery. The target motor in the driving assembly is a brushless hollow cup motor, which is composed of a rotor and a stator. The angle between the magnetic induction lines of the rotor magnetic field and the stator magnetic field is a fixed angle, which is an angle between 40 degrees and 50 degrees. The controller comprises a level determination module, a current determination module, a current mapping module, a current fusion module, a voltage determination module and a motor control module. By using the embodiment, the control of the right ventricular assist device can be adapted to the real-time change state of the heart.

This disclosure provides a dry powder composition of treprostol prodrug and a method of treating pulmonary hypertension (e.g., pulmonary arterial hypertension or PH associated with interstitial lung disease) in patients in need using said dry powder composition. The dry powder composition comprises: (a) about 0.5 wt% to about 5 wt% of a compound, its stereoisomers, or a pharmaceutically acceptable salt thereof; (b) about 10 wt% to about 61 wt% of leucine; and the remainder is (c) a sugar selected from the group consisting of trehalose and mannitol. The total of (a), (b), and (c) is 100 wt%, and R1 is tetradecyl, pentadecyl, hexadecyl, heptadecanyl, or octadecyl. The method of treating PH comprises administering an effective amount of the dry powder composition to the lungs of the patient by inhalation via a dry powder inhaler during an administration period.

The application belongs to the technical field of biotechnology, and discloses a set of biomarkers for predicting the risk of idiopathic pulmonary arterial hypertension and application thereof. The application integrates expression quantitative trait locus (eQTL) data and single-cell RNA sequencing (scRNA-seq) data sets from peripheral blood and lung tissue and whole genome association analysis (GWAS) summary statistics of idiopathic pulmonary arterial hypertension, uses Mendelian randomization algorithm (MR), genome enrichment analysis and immunofluorescence experiments to identify and accurately locate related genes, and for the first time discovers biomarkers related to the risk of idiopathic pulmonary arterial hypertension, which include at least one of CST7, HLA-B, HLA-E, FKBP1A and UBB. By detecting the above biomarkers, the risk of idiopathic pulmonary arterial hypertension can be effectively diagnosed.

The application discloses an ex vivo heart perfusion system and a perfusion control method, wherein the perfusion system comprises: an organ bin, which is externally provided with a constant temperature heating film for controlling the temperature in the organ bin to be a first preset temperature threshold; a liquid storage container for containing a perfusion medium, an outlet end of the liquid storage container being connected to a first active branch vein through a first liquid supply pipe and connected to a pulmonary vein through a second liquid supply pipe, an inlet end of the liquid storage container being connected to a second active branch vein through a first liquid return pipe and connected to a pulmonary artery through a second liquid return pipe; a circulating pump connected to the first liquid supply pipe; an oxygenator connected to the first liquid supply pipe, the oxygenator being connected with a gas supply module for adjusting the gas mixing ratio in the perfusion medium; and an injection pump group for supplementing injection of nutrient substances or therapeutic drugs. The application can effectively prolong the heart supply storage time, reduce the heart supply discard rate, and further improve the utilization rate of the heart supply.

The present invention relates to a biodegradable, absorbable stent comprising a skeletal structure made of a metallic alloy of magnesium and a transition metal and / or a rare earth element. The skeletal structure is coated with a polymer, and the coated skeletal structure has struts of stent elements, and the stent may be a valve support stent. Furthermore, the present invention relates to the use of a disclosed valveless stent, or a system comprising a corresponding stent, for implantation in congenital heart disease to open the pulmonary artery, to maintain patency of the ductus arteriosus (ductus of Botallo), to maintain patency of aortic isthmus stenosis, to stimulate growth in a hypoplastic pulmonary artery, or as an esophageal stent or ureteral support.

A pulmonary artery flow restrictor system includes a funnel shaped membrane with a proximal base, a restrictive distal opening which is stretchable to larger sizes, an internal strut structure, and an external stent structure.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present invention relates to high-dose macitentan, i.e., propylsulfamic acid [5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide, or a pharmaceutically acceptable salt, solvate, hydrate, or morphological form thereof, or aprocitentan, for use in the treatment and / or prevention of pulmonary arterial hypertension (PAH). Furthermore, the present invention relates to the use of high-dose macitentan or aprocitentan for the manufacture of a medicament for the treatment and / or prevention of PAH, and to methods for the treatment and / or prevention of PAH comprising high-dose macitentan or aprocitentan. Furthermore, the present invention relates to dosing regimens for the treatment and / or prevention of PAH, and to combinations of one or more phosphodiesterase type 5 (PDE5) inhibitors, prostacyclin analogs, prostacyclin receptor agonists, or soluble guanylate cyclase stimulators. Wherein, the PAH is preferably mild or moderate PAH.Furthermore, the present invention relates to a pharmaceutical composition for treating PAH, comprising a high dose of macitentan or aprocitentan.

The present invention in some embodiments thereof relates to a method for selectively modifying nerve activity without causing substantial damage to non-targeted tissue, comprising introducing a catheter device comprising one or more ultrasonic transceivers to the pulmonary artery lumen, receiving, using the one or more ultrasonic transceivers, echo signals reflected from the non-targeted tissue following emission of ultrasound energy by the one or more transceivers, analyzing the received echo signals to identify at least one of a type and location of the non-targeted tissue relative to the one or more transceivers, and emitting ultrasound energy from the one or more ultrasonic transceivers in accordance with the analysis, to modify nerve activity without substantially damaging the identified non-targeted tissue.

The invention belongs to the field of nucleic acid reagents, and particularly relates to a reagent and a method for silencing HIF2A. The dsRNA reagent provided by the invention can efficiently inhibit the expression of the HIF2A, so that the dsRNA reagent can be used for treating or preventing diseases related to the HIF2A, such as cancers, cardiovascular diseases and pulmonary arterial hypertension.

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

The present disclosure provides anti-platelet-derived growth factor subunit B (PDGF-B) antibodies and antigen-binding fragments thereof, and methods of using such antibodies or antigen-binding fragments thereof to treat subjects with pulmonary arterial hypertension (PAH).

The application relates to a blood pump, which comprises a driving unit for driving blood flow and a sleeve shell sleeved on the periphery of the driving unit, the proximal end of the sleeve shell being fixedly connected with the proximal end of the driving unit or a catheter of the blood pump, the inner peripheral surface of the sleeve shell and the driving unit being radially spaced to form a blood flow channel, the sleeve shell comprising a first shell and a second shell, the proximal end of the first shell being fixedly connected with the driving unit or the catheter, the distal end of the first shell being abutted with the second shell to form a straight cylinder structure, the first shell being provided with a liquid inlet, the second shell being provided with a liquid outlet, and the liquid outlet being communicated with the liquid inlet through the blood flow channel. In this way, the axial dimension of the pump body of the blood pump can be designed to be smaller, so that the blood pump can pass through the pushing path from the inferior vena cava (or the superior vena cava) to the pulmonary artery to assist the right ventricle in pumping blood into the pulmonary artery, and the risk of excessive expansion and inflation of the right ventricle during the blood filling process is reduced.

This invention discloses a method and system for constructing an AI-assisted diagnostic agent for pulmonary embolism based on ontology and knowledge graph, belonging to the fields of medical information systems and medical artificial intelligence technology. By integrating a pulmonary embolism-specific medical ontology, a clinically aligned knowledge graph, and thought chain reasoning, this invention leverages the hard constraints of ontology knowledge to achieve interpretability analysis of the entire process of AI-assisted diagnosis for pulmonary embolism, precise suppression of AI illusions specific to pulmonary embolism, end-to-end quality control, and closed-loop optimization. It is particularly suitable for rapid diagnosis of acute and critical pulmonary embolism, AI-assisted identification of pulmonary artery filling defects in CTPA images, thrombosis severity stratification, and emergency treatment decision tracing and regulatory compliance quality control scenarios. It can be adapted to the implementation, regulatory verification, and clinical optimization of various pulmonary embolism AI imaging diagnostic and emergency auxiliary diagnosis and treatment systems, specifically addressing core illusion problems in pulmonary embolism AI diagnosis such as false positive embolus identification and disordered risk stratification.

A method for improving an ejection fraction of a patient in need thereof, including positioning a pulmonary artery manipulation device in a target blood vessel, within the pulmonary vasculature of the patient; and impairing the activity of at least one sympathetic nerve, nerve fiber or neuron, using the pulmonary artery manipulation device, to denervate the target blood vessel, thereby improving the ejection fraction of the patient.

The present invention relates to mRNA drugs and their use in the treatment of pulmonary arterial hypertension. In particular, the present invention relates to polynucleotides encoding a peptide comprising a BMP9 active molecule and / or an ACTRIIA ligand trap, lipid nanoparticles comprising said polynucleotides and their therapeutic use.

A system for treating atrial dysfunction, including heart failure and / or atrial fibrillation, that includes one or more pressurizing elements and control circuitry. The one or more pressurizing elements can comprise one or more balloons and can be configured to be positioned in the left atrium, and optionally the pulmonary artery, of a patient's heart. The one or more pressurizing elements can be coupled to one or more positioning structures that can be configured to position the one or more pressurizing elements in the left atrium, and optionally the pulmonary artery. The control circuitry can be configured to operate the one or more pressurizing elements to decrease or increase pressure and / or volume in the left atrium, and optionally the pulmonary artery, in accordance with different phases of the cardiac cycle. The control circuitry can be further configured to operate the one or more pressurizing elements to generate coordinated pressure modifications in the left atrium, and optionally the pulmonary artery.

The present invention relates to the use of bacterial compositions having an arginine deiminase activity (inhibition of nitric oxide synthase by conversion of L-arginine to L-citrulline) of 1-1,000 μmol L-citrulline / h / g composition and a sphingomyelinase (ceramide generation) activity of 0.01-1.000 nmoles ceramides / h / g composition in the treatment and / or prophylaxis of airway diseases caused by viruses such as influenza viruses, coronaviruses, as SARS-CoV, MERS-CoV and SARS-CoV-2, avian viruses, respiratory syncytial virus (VRS), rhinoviruses, pneumoviruses, or respiratory failure induced or aggravated by viral infections, angina pectoris, pulmonary heart, respiratory distress, pulmonary edema, neonatal asphyxia, myocardial infarction, heart failure, respiratory failure Pickwick syndrome, pulmonary hypertension, pneumonia or even cystic fibrosis (CF) aggravated by viral infections.